What is EmendoBio?
EmendoBio is at the forefront of innovating traditional CRISPR solutions to enhance human health and address previously untreatable diseases. The company's core focus lies in understanding genetic diseases to develop customized gene editing strategies that optimize nucleases and guide-RNAs for effective therapeutic interventions. With a steadfast commitment to overcoming existing challenges in the field, EmendoBio aims to unlock the full potential of CRISPR technology. Their services are meticulously tailored to meet the unique needs of each genetic disease, ensuring high editing activity while diligently minimizing off-target effects.
How much funding has EmendoBio raised?
EmendoBio has raised a total of $61M across 1 funding round:
Series B
$61M
Series B (2020): $61M with participation from AnGes, Inc.
Key Investors in EmendoBio
AnGes, Inc.
AnGes, Inc. is an investor participating in EmendoBio's funding round. Further details on their specific investment focus are not provided.
What's next for EmendoBio?
The company's recent major strategic investment, coupled with its substantial total funding, indicates EmendoBio is likely in a growth or scaling phase, potentially Series B or beyond. This capital infusion is expected to fuel further research and development, accelerate the optimization of their gene editing platforms, and potentially support clinical trial advancements. EmendoBio's strategic focus on enhancing CRISPR technology for complex genetic diseases positions it for significant impact and future expansion within the biotechnology landscape.
See full EmendoBio company page
